Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Avanafil

FDA-approved product (tablet, oral), marketed as Avanafil, Stendra.

Registered studies
24
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Avanafil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Erectile dysfunction
  • Impotence

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in erectile dysfunction
FDA pharmacologic class
Phosphodiesterase 5 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Avanafil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Avanafil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects

    NCT00914511 · start 2009-05

    Registered record
    Registry ID
    NCT00914511
    Conditions
    Avanfil ADME; Semen Exposure; Sperm Function
    Interventions
    avanafil 200mg; avanafil 200mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-05
    Completion
    2009-06
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAvanfil ADME; Semen Exposure; Sperm Function
    Interventionavanafil 200mg; avanafil 200mg
    PhasePhase 1
    Registry statusCompleted

  • Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy

    NCT00895011 · start 2009-04

    Registered record
    Registry ID
    NCT00895011
    Conditions
    Erectile Dysfunction
    Interventions
    Placebo; Avanafil; Avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2011-04
    Enrolment
    298

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionPlacebo; Avanafil; Avanafil
    PhasePhase 3
    Registry statusCompleted

  • Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction

    NCT00853606 · start 2009-03

    Registered record
    Registry ID
    NCT00853606
    Conditions
    Erectile Dysfunction
    Interventions
    avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-04
    Enrolment
    712

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    Interventionavanafil
    PhasePhase 3
    Registry statusCompleted

  • Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil

    NCT00903981 · start 2009-03

    Registered record
    Registry ID
    NCT00903981
    Conditions
    Erectile Dysfunction
    Interventions
    Avanafil; Avanafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-03
    Completion
    2009-11
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionAvanafil; Avanafil; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)

    NCT00809471 · start 2008-12

    Registered record
    Registry ID
    NCT00809471
    Conditions
    Erectile Dysfunction
    Interventions
    placebo; avanafil; avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    2010-02
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    Interventionplacebo; avanafil; avanafil
    PhasePhase 3
    Registry statusCompleted

  • Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED

    NCT00790751 · start 2008-11

    Registered record
    Registry ID
    NCT00790751
    Conditions
    Erectile Dysfunction
    Interventions
    placebo; avanafil; avanafil; avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-11
    Completion
    2009-08
    Enrolment
    646

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    Interventionplacebo; avanafil; avanafil; avanafil
    PhasePhase 3
    Registry statusCompleted

  • A Thorough EKG Safety Study of TA-1790 (Avanafil)

    NCT00769041 · start 2008-10

    Registered record
    Registry ID
    NCT00769041
    Conditions
    Erectile Dysfunction
    Interventions
    moxifloxacin; avanafil; avanafil; sugar pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-01
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    Interventionmoxifloxacin; avanafil; avanafil; sugar pill
    PhasePhase 1
    Registry statusCompleted

  • To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil

    NCT00770042 · start 2008-10

    Registered record
    Registry ID
    NCT00770042
    Conditions
    Erectile Dysfunction
    Interventions
    Ritonavir; Ketoconazole; Erythomycin; Avanafil; Avanafil; Avanafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2008-12
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionRitonavir; Ketoconazole; Erythomycin; Avanafil +2 more
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction

    NCT02477436 · start 2008-02

    Registered record
    Registry ID
    NCT02477436
    Conditions
    Erectile Dysfunction
    Interventions
    Avanafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2008-09
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionAvanafil; Placebo
    PhasePhase 2
    Registry statusCompleted